SCM
CCCC icon

Sterling Capital Management’s C4 Therapeutics CCCC Stock Holding History

Sterling Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.54K Buy
+2,043
New +$6.99K ﹤0.01% 2244
2025
Q2 		– Sell
-1,081
Closed -$1.73K – 3286
2025
Q1 		$1.73K Sell
1,081
-797
-42% -$2.38K ﹤0.01% 2645
2024
Q4 		$6.76K Buy
1,878
+1,692
+910% +$8.41K ﹤0.01% 2324
2024
Q3 		$1.06K Buy
+186
New +$1.12K ﹤0.01% 2491

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sterling Capital Management's CCCC Position: Q2 2026 in Review

Sterling Capital Management opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 2,043 shares worth $9.54K. The stake represents ﹤0.01% of the portfolio and ranks #2244 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in CCCC as recently as Q1 2025.

Sterling Capital Management first reported a position in CCCC in Q3 2024 and has held it in 4 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Sterling Capital Management held 2,043 shares of C4 Therapeutics worth $9.54K as of Q2 2026.
  • C4 Therapeutics was a new Sterling Capital Management position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2244 holding.
  • Sterling Capital Management first reported a position in C4 Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.